Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$203.66 USD
+2.83 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $203.79 +0.13 (0.06%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KRYS 203.66 +2.83(1.41%)
Will KRYS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Replimune (REPL) Gains on Positive Data From Melanoma Study
Other News for KRYS
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
TimesSquare Capital U.S. Small/Mid Cap Growth Q1 2024 Commentary